Effect of continuous positive airway pressure therapy on sexual function and serum testosterone in males with type 2 diabetes and obstructive sleep apnoea

2014 ◽  
Vol 81 (2) ◽  
pp. 254-258 ◽  
Author(s):  
Arthur Knapp ◽  
Paul C. Myhill ◽  
Wendy A. Davis ◽  
Kirsten E. Peters ◽  
David Hillman ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Continuous Positive Airway Pressure ◽  
Sexual Function ◽  
Airway Pressure ◽  
Positive Airway Pressure ◽  
Serum Testosterone ◽  
Sleep Apnoea ◽  
Pressure Therapy ◽  
Obstructive Sleep

scholarly journals Continuous positive airway pressure effect on visual acuity in patients with type 2 diabetes and obstructive sleep apnoea: a multicentre randomised controlled trial

2018 ◽  
Vol 52 (4) ◽  
pp. 1801177 ◽  
Author(s):  
Sophie D. West ◽  
Benjamin Prudon ◽  
Joan Hughes ◽  
Rajen Gupta ◽  
Seid B. Mohammed ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Visual Acuity ◽  
Continuous Positive Airway Pressure ◽  
Obstructive Sleep Apnoea ◽  
Airway Pressure ◽  
Positive Airway Pressure ◽  
Sleep Apnoea ◽  
Obstructive Sleep ◽  
Significant Difference

We sought to establish whether continuous positive airway pressure (CPAP) for obstructive sleep apnoea (OSA) in people with type 2 diabetes and diabetic macular oedema (DMO) improved visual acuity.We randomly assigned 131 eligible patients aged 30–85 years from 23 UK centres with significant DMO causing visual impairment (LogMAR letters identified ≥39 and ≤78, score 0.92–0.14) plus severe OSA on screening to either usual ophthalmology care (n=67) or usual ophthalmology care plus CPAP (n=64) for 12 months.Mean age of participants was 64 years, 73% male, mean body mass index 35.0 kg·m−2. Mean 4% oxygen desaturation index was 36 events·h−1. There was no significant difference in the visual acuity at 12 months between the CPAP group and the control group (mean LogMAR 0.33 (95% CI 0.29–0.37) versus 0.31 (95% CI 0.27–0.35); p=0.39), and no significant correlation between change in LogMAR and average CPAP use. The median±sd (range) daily CPAP use was 3.33±2.25 (0–7.93) h at 3 months, 3.19±2.54 (0–8.07) h at 6 months and 3.21±2.70 (0–7.98) h at 12 months.CPAP therapy for OSA did not improve visual acuity in people with type 2 diabetes and DMO compared with usual care alone over 12 months.

Sign in / Sign up

Export Citation Format

Share Document